Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'.

Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR.

Phys Med Biol. 2016 Apr 7;61(7):2968-9. doi: 10.1088/0031-9155/61/7/2968. Epub 2016 Mar 17. No abstract available.

PMID:
26988701
2.

A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.

Blumenthal DT, Rankin C, Stelzer KJ, Spence AM, Sloan AE, Moore DF Jr, Padula GD, Schulman SB, Wade ML, Rushing EJ.

Int J Clin Oncol. 2015 Aug;20(4):650-8. doi: 10.1007/s10147-014-0769-0. Epub 2014 Nov 19.

3.

VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES.

O'Sullivan F, Muzi M, Mankoff DA, Eary JF, Spence AM, Krohn KA.

Ann Appl Stat. 2014 Jun 1;8(2):1065-1094.

4.

Carboplatin and bevacizumab for recurrent malignant glioma.

Mrugala MM, Crew LK, Fink JR, Spence AM.

Oncol Lett. 2012 Nov;4(5):1082-1086. Epub 2012 Aug 1.

5.

Radiation associated tumors following therapeutic cranial radiation.

Chowdhary A, Spence AM, Sales L, Rostomily RC, Rockhill JK, Silbergeld DL.

Surg Neurol Int. 2012;3:48. doi: 10.4103/2152-7806.96068. Epub 2012 May 14.

6.

Epigenetic licensing of germline gene expression by maternal RNA in C. elegans.

Johnson CL, Spence AM.

Science. 2011 Sep 2;333(6047):1311-4. doi: 10.1126/science.1208178.

7.

Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.

Gu S, Chakraborty G, Champley K, Alessio AM, Claridge J, Rockne R, Muzi M, Krohn KA, Spence AM, Alvord EC Jr, Anderson AR, Kinahan PE, Swanson KR.

Math Med Biol. 2012 Mar;29(1):31-48. doi: 10.1093/imammb/dqr002. Epub 2011 May 11.

8.

A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.

Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, Forsyth PA, Appley AJ, Spence AM, Hinton DR, Chen TC.

Cancer. 2011 Nov 1;117(21):4905-15. doi: 10.1002/cncr.26123. Epub 2011 Mar 31.

9.

Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival.

Ramakrishna R, Barber J, Kennedy G, Rizvi A, Goodkin R, Winn RH, Ojemann GA, Berger MS, Spence AM, Rostomily RC.

Surg Neurol Int. 2010 Aug 10;1. pii: 40. doi: 10.4103/2152-7806.68337.

10.

Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach.

Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC Jr, Swanson KR.

Phys Med Biol. 2010 Jun 21;55(12):3271-85. doi: 10.1088/0031-9155/55/12/001. Epub 2010 May 18.

11.

Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.

Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC Jr, Swanson KR.

Cancer Res. 2009 Dec 1;69(23):9133-40. doi: 10.1158/0008-5472.CAN-08-3863. Epub 2009 Nov 24.

12.

Nonparametric Residue Analysis of Dynamic PET Data With Application to Cerebral FDG Studies in Normals.

O'Sullivan F, Muzi M, Spence AM, Mankoff DM, O'Sullivan JN, Fitzgerald N, Newman GC, Krohn KA.

J Am Stat Assoc. 2009 Jun 1;104(486):556-571.

13.

Kinetic quantitation of cerebral PET-FDG studies without concurrent blood sampling: statistical recovery of the arterial input function.

O'Sullivan F, Kirrane J, Muzi M, O'Sullivan JN, Spence AM, Mankoff DA, Krohn KA.

IEEE Trans Med Imaging. 2010 Mar;29(3):610-24. doi: 10.1109/TMI.2009.2029096. Epub 2009 Aug 25.

14.

Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.

Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr, Krohn KA, Spence AM, Swanson KR.

Cancer Res. 2009 May 15;69(10):4502-9. doi: 10.1158/0008-5472.CAN-08-3884. Epub 2009 Apr 14.

15.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA.

Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55. doi: 10.1007/s11307-009-0215-2. Epub 2009 Mar 27.

16.

Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.

Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, Adamsen TC, Krohn KA, Spence AM.

J Nucl Med. 2009 Jan;50(1):36-44. doi: 10.2967/jnumed.108.055467. Epub 2008 Dec 17.

17.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies.

Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA.

Mol Imaging Biol. 2008 Sep;10(5):271-80. doi: 10.1007/s11307-008-0151-6. Epub 2008 Jun 10.

18.

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.

Blumenthal DT, Rankin C, Eyre HJ, Livingston RB, Spence AM, Stelzer KJ, Rushing EJ, Berger MS, Rivkin SE, Cohn AL, Petersdorf SH.

Cancer. 2008 Aug 1;113(3):559-65. doi: 10.1002/cncr.23585.

19.

Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA.

Clin Cancer Res. 2008 May 1;14(9):2623-30. doi: 10.1158/1078-0432.CCR-07-4995.

20.

Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM.

Neuro Oncol. 2008 Feb;10(1):88-92. Epub 2007 Nov 30.

21.

Challenges in clinical studies with multiple imaging probes.

Krohn KA, O'Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR.

Nucl Med Biol. 2007 Oct;34(7):879-85. Review.

22.

A CUL-2 ubiquitin ligase containing three FEM proteins degrades TRA-1 to regulate C. elegans sex determination.

Starostina NG, Lim JM, Schvarzstein M, Wells L, Spence AM, Kipreos ET.

Dev Cell. 2007 Jul;13(1):127-39.

23.

Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.

Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA.

Clin Cancer Res. 2007 Jun 15;13(12):3460-9. Review.

24.

What is in a number? The FDG lumped constant in the rat brain.

Krohn KA, Muzi M, Spence AM.

J Nucl Med. 2007 Jan;48(1):5-7. No abstract available.

25.
26.

Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.

Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, Link JM, Krohn KA.

J Nucl Med. 2006 Oct;47(10):1612-21.

27.

Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.

Partap S, Spence AM.

J Neurooncol. 2006 Dec;80(3):305-7. Epub 2006 Jun 23.

PMID:
16794747
28.

Hypoxia imaging-directed radiation treatment planning.

Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA.

Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:44-53. Review.

PMID:
16763816
29.

Complications of a temozolomide overdose: a case report.

Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA.

J Neurooncol. 2006 Oct;80(1):57-61. Epub 2006 Apr 28.

PMID:
16645714
30.

Prolonged but reversible migraine-like episodes long after cranial irradiation.

Partap S, Walker M, Longstreth WT Jr, Spence AM.

Neurology. 2006 Apr 11;66(7):1105-7.

PMID:
16606929
31.

Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.

Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, Lindau M, Lockman PR, Manninger SP, Qiang Y, Spence AM, Stupp SI, Zhang M, Neuwelt EA.

AJNR Am J Neuroradiol. 2006 Mar;27(3):715-21.

32.

Bromophenol blue staining of tumors in a rat glioma model.

Ozawa T, Britz GW, Kinder DH, Spence AM, VandenBerg S, Lamborn KR, Deen DF, Berger MS.

Neurosurgery. 2005 Nov;57(5):1041-7; discussion 1041-7.

PMID:
16284574
33.
34.

True tracers: comparing FDG with glucose and FLT with thymidine.

Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM.

Nucl Med Biol. 2005 Oct;32(7):663-71. Review.

PMID:
16243640
35.

[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.

Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, Silbergeld DL, Rostomily RC, Scharnhorst J, Spence AM.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):886-91. Epub 2005 Oct 19.

PMID:
16242251
36.

Central nervous system cancers: Clinical Practice Guidelines in Oncology.

Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Sills AK Jr, Spence AM, Vrionis FD; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Sep;3(5):644-90. No abstract available.

PMID:
16194456
37.

Myocarditis from the Chinese sumac tree.

Bisognano JD, McGrody KS, Spence AM.

Ann Intern Med. 2005 Jul 19;143(2):159-60. No abstract available.

PMID:
16027471
38.

Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy.

Bobola MS, Emond MJ, Blank A, Meade EH, Kolstoe DD, Berger MS, Rostomily RC, Silbergeld DL, Spence AM, Silber JR.

Clin Cancer Res. 2004 Dec 1;10(23):7875-83.

39.

Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.

Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL, Rostomily RC.

J Neurooncol. 2004 Oct;70(1):91-5.

PMID:
15527114
40.

18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.

Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA.

J Nucl Med. 2004 Oct;45(10):1653-9.

41.

TRA-1/GLI controls development of somatic gonadal precursors in C. elegans.

Mathies LD, Schvarzstein M, Morphy KM, Blelloch R, Spence AM, Kimble J.

Development. 2004 Sep;131(17):4333-43. Epub 2004 Aug 4.

42.
43.

Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.

Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA.

Clin Cancer Res. 2004 Apr 1;10(7):2245-52.

44.

Positron emission tomography imaging of brain tumors.

Spence AM, Mankoff DA, Muzi M.

Neuroimaging Clin N Am. 2003 Nov;13(4):717-39. Review.

PMID:
15024957
45.

[18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro.

Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM.

Nucl Med Biol. 2004 Jan;31(1):1-9.

PMID:
14741565
46.

Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody.

Samii A, Dahlen DD, Spence AM, Maronian NC, Kraus EE, Lennon VA.

Mov Disord. 2003 Dec;18(12):1556-8. Review.

PMID:
14673901
47.

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.

Chang SM, Kuhn JG, Ian Robins H, Clifford Schold S, Spence AM, Berger MS, Mehta MP, Pollack I, Gilbert M, Prados MD.

Invest New Drugs. 2003 Nov;21(4):429-33.

PMID:
14586210
48.

Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis.

Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM, Krohn KA.

Mol Imaging. 2002 Jul;1(3):151-9.

PMID:
12920853
49.

Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results.

Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F, Vernon CB, Link JM, Krohn KA.

Mol Imaging. 2002 Jul;1(3):145-50.

PMID:
12920852

Supplemental Content

Loading ...
Support Center